5'-deoxytoyocamycin: from Streptomyces sp. A14345; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 128252 |
| CHEMBL ID | 99388 |
| SCHEMBL ID | 6877410 |
| MeSH ID | M0192044 |
| Synonym |
|---|
| CHEMBL99388 , |
| 5'-deoxytoyocamycin |
| 4-amino-7-(3,4-dihydroxy-5-methyl-tetrahydro-furan-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile |
| 4-amino-7-((2r,3r,4s,5r)-3,4-dihydroxy-5-methyl-tetrahydro-furan-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile |
| 4-amino-7-((2r,3r,4s,5r)-3,4-dihydroxy-5-methyl-tetrahydrofuran-2-yl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile |
| bdbm50090861 |
| 65562-55-2 |
| 4-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-methyloxolan-2-yl]pyrrolo[2,3-d]pyrimidine-5-carbonitrile |
| 7h-pyrrolo(2,3-d)pyrimidine-5-carbonitrile, 4-amino-7-(5-deoxy-beta-d-ribofuranosyl)- |
| SCHEMBL6877410 |
| DTXSID60984150 |
| 4-amino-7-(5-deoxypentofuranosyl)-7h-pyrrolo[2,3-d]pyrimidine-5-carbonitrile |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Adenosine kinase | Homo sapiens (human) | IC50 (µMol) | 1,076,163.5400 | 0.0005 | 0.6052 | 10.0000 | AID33985; AID33990; AID33993 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| purine ribonucleoside salvage | Adenosine kinase | Homo sapiens (human) |
| dATP biosynthetic process | Adenosine kinase | Homo sapiens (human) |
| ribonucleoside monophosphate biosynthetic process | Adenosine kinase | Homo sapiens (human) |
| GMP salvage | Adenosine kinase | Homo sapiens (human) |
| AMP salvage | Adenosine kinase | Homo sapiens (human) |
| dAMP salvage | Adenosine kinase | Homo sapiens (human) |
| purine nucleobase metabolic process | Adenosine kinase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| RNA binding | Adenosine kinase | Homo sapiens (human) |
| deoxyadenosine kinase activity | Adenosine kinase | Homo sapiens (human) |
| ATP binding | Adenosine kinase | Homo sapiens (human) |
| metal ion binding | Adenosine kinase | Homo sapiens (human) |
| adenosine kinase activity | Adenosine kinase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| nucleoplasm | Adenosine kinase | Homo sapiens (human) |
| cytosol | Adenosine kinase | Homo sapiens (human) |
| plasma membrane | Adenosine kinase | Homo sapiens (human) |
| nucleus | Adenosine kinase | Homo sapiens (human) |
| cytosol | Adenosine kinase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID382097 | Inhibition of adenosine kinase | 2008 | Bioorganic & medicinal chemistry, May-01, Volume: 16, Issue:9 | A CoMSIA study on the adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues. |
| AID33993 | Inhibition concentration against human adenosine kinase | 2002 | Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6 | QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach. |
| AID33985 | Inhibition of recombinant human adenosine kinase | 2000 | Journal of medicinal chemistry, Jul-27, Volume: 43, Issue:15 | Adenosine kinase inhibitors. 1. Synthesis, enzyme inhibition, and antiseizure activity of 5-iodotubercidin analogues. |
| AID33990 | Inhibition of human adenosine kinase activity | 2002 | Bioorganic & medicinal chemistry letters, Mar-25, Volume: 12, Issue:6 | QSAR study on adenosine kinase inhibition of pyrrolo[2,3-d]pyrimidine nucleoside analogues using the hansch approach. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.58) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||